**Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice**

Mitchell R Smith*1, Indira Joshi1, Fang Jin1 and Coleman Obasaju1,2

Address: 1Department of Medical Oncology Fox Chase Cancer Center 333 Cottman Avenue Philadelphia, PA19111, USA and 2Lilly Research Laboratories, Indianapolis, IN, USA

Email: Mitchell R Smith* - m_smith@fccc.edu; Indira Joshi - indira.joshi@fccc.edu; Fang Jin - f_jin@fccc.edu; Coleman Obasaju - cobasaju@lilly.com

* Corresponding author

**Abstract**

**Background:** Despite exciting new targeted therapeutics against non-Hodgkin’s lymphoma (NHL), chemotherapy remains a cornerstone of therapy. While purine nucleoside analogs have significant activity in low grade NHL, the pyrimidine nucleoside analog gemcitabine has been less extensively studied, but has important activity. Use of the anti-CD20 monoclonal antibody rituximab in combination with chemotherapy for B-NHL is becoming prevalent in clinical practice, but has not been extensively studied in pre-clinical models.

**Methods:** We have tested the activity of gemcitabine ± rituximab in vitro and in scid/human NHL xenograft models. We used two t(14;18)+, CD20+ follicular B cell NHL cell lines, DoHH2 a transformed NHL line and WSU-FSCCL isolated from pleural fluid of a patient with indolent NHL.

**Results:** Gemcitabine is cytotoxic to DoHH2 and WSU-FSCCL cells in vitro, and the IC50 is 2–3 fold lower in the presence of rituximab. Apoptosis is also enhanced in the presence of rituximab. Clearance of NHL cells from ascites in scid mice is prolonged by the combination, as compared with either agent alone. Most importantly, survival of scid mice bearing human NHL cells is significantly prolonged by the combination of gemcitabine + rituximab.

**Conclusion:** Based on our pre-clinical data showing prolonged survival of mice bearing human lymphoma cell line xenografts after treatment with gemcitabine + anti-CD20 antibody, this combination, expected to have non-overlapping toxicity profiles, should be explored in clinical trials.

**Background**

Non-Hodgkin’s lymphoma (NHL) is increasing in incidence and is now the fifth most common malignancy in the U.S. Despite novel targeted biologic treatment options, chemotherapy remains an important component of therapy. Furthermore, most patients with indolent lymphoma and at least half of all patients with aggressive NHL are not cured [1]. Improved therapeutic approaches are needed.

Gemcitabine is a pyrimidine nucleoside analog with clinical anti-cancer activity. Purine nucleoside analogs such as
Apoptosis and cell cycle

Cell cycle was analyzed by DNA content per cell, by propidium iodide (PI) staining of nuclei from hypotonically lysed cells [20]. Apoptosis was determined by dual staining of 1 × 10^5 intact cells in 100 µl calcium binding buffer containing 5 µl of fluorescein isothiocyanate (FITC)-labeled annexin V (Pharminen) and 5 µg/ml PI for 15 minutes in the dark, followed by analysis by flow cytometry (FACScan).

Poly(ADP-ribose) polymerase (PARP) cleavage assay

DoHH2 and WSU-FSCCL cells were lysed in cold radioimmunoprecipitation assay (RIPA) buffer [21] containing 100 µg phenylmethanesulfonl fluoride (PMSF)/ml and 1 µg aprotinin/ml for 30 min on ice, pelleted and the supernatant separated by 4–20% SDS-PAGE. Transfer was to Immobilon-P, blocked with 1% casein-0.04% Tween-20 and probed with anti-PARP C2–10 antibody (Trevigen, Gaithersburg, MD). Secondary antibody was horseradish peroxidase labeled anti-mouse IgG (1:3000) for 30 min, detected by chemiluminescence and Hyperfilm ECL (Amersham, Piscataway, NJ). Densitometry utilized NIH Image 1.61 software.

Scid/human xenograft

Female CB17 scid mice were bred, housed and treated in the Fox Chase Cancer Center Laboratory Animal Facility under an approved protocol. Mice 4–8 weeks old were injected ip with either 1 × 10^7 WSU-FSCCL cells or 5 × 10^6 DoHH2 cells. Mice were observed daily and euthanized when they appeared ill. Lymphoma involving diffuse adenopathy, splenomegaly, infiltration of liver and bone marrow, along with ascites developed in untreated mice with each model, at 8–11 weeks with WSU-FSCCL and 4–6 weeks with DoHH2. Cells were collected sequentially from ascites by peritoneal washings and analyzed, or mice were followed for survival. For ascites clearance, mice bearing DoHH2 received 20 µg rituximab intraperitoneally (ip) on day 3 after lymphoma cell injection and/or gemcitabine 120 µg/gm ip on day 4, while mice bearing WSU-FSCCL received 100 µg rituximab intraperitoneally (ip) on day 7 after lymphoma cell injection, and/or gemcitabine 120 µg/gm ip on day 8. For survival, mice bearing DoHH2 received 5 µg rituximab on days 2, 9 and 16 and/or gemcitabine 120 µg/gm ip on days 3, 10 and 17.

Results

Cell growth inhibition by gemcitabine and rituximab

Both DoHH2 and WSU-FSCCL cells are growth inhibited by gemcitabine with an IC_{50} of 1 nM after 72 hr incubation (Figure 1). Addition of rituximab alone or in combination with gemcitabine had little effect on WSU-FSCCL cells in vitro. In contrast, DoHH2 cells are growth inhibited about 35% by 20 µg/ml rituximab. The maximal rituximab effect is seen at 1 µg/ml. This is accord with data

Methods

Cell culture and growth assay

Cells are incubated under standard conditions and cell numbers are determined by methyl thiazol tetrazolium-bromide (MTT) assay as before [17]. Briefly, DoHH2 [18], a t(14;18)+ transformed lymphoma cell line, was obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany). WSU-FSCCL, as previously reported [19], was isolated from pleural fluid of a patient with follicular grade I lymphoma, contains t(14;18), is EBV negative and behaves in scid mice as a more indolent disease [17], although it does contain a c-myc translocation.

Anti-CD20 monoclonal antibody

Chimeric anti-CD20 (clone C2B8, rituximab) obtained from IDEC (San Diego, CA), and gemcitabine (generously supplied by Lilly, Indianapolis, IN) were injected intraperitoneally (ip).

fludarabine, cladribine and pentostatin have been extensively studied and have significant activity against certain non-Hodgkin's lymphoma subtypes, particularly indolent forms. Though less well studied, an increasing body of data indicates activity of gemcitabine against lymphoma, both Hodgkin's and NHL [2-7]. The precise place of gemcitabine in the therapeutic armamentarium for NHL remains to be elucidated.

The chimeric anti-CD20 monoclonal antibody rituximab is active as a single agent in B cell NHL [8]. In addition, it may sensitize cells to the action of chemotherapeutic and other biologic agents pre-clinically [9-12], as well as in patients [13,14]. While mechanisms of rituximab action include direct apoptotic induction, complement activation and antibody dependent cytotoxicity, which of these is important may depend on the experimental conditions, and the relative importance in patients remains to be determined (reviewed in [15]). The same mechanisms, as well as intracellular signaling [16], may account for chemosensitization, but again the exact means by which this occurs in patients remains to be fully elucidated. One previous report has demonstrated in vitro sensitization of aggressive B cell NHL cell lines to gemcitabine by rituximab [10]. Here we extend these in vitro results to additional human CD20+ lymphoma cell lines that carry the t(14:18) translocation, perhaps more analogous to the lymphoma, contains t(14;18), is EBV negative and Behaves in a human B-NHL cell line/scid mouse xenograft model.

Page 2 of 9
that CD20 sites are saturated at this level, while effective serum levels in patients are felt to be 25 µg/ml. Thus, there is essentially no dose response at clinically achievable levels. This precludes the calculation of synergy by the standard approach [22], as has been concluded by other investigators as well [23]. Because of our prior experience that oligonucleotides can interfere with drug and antibody uptake, we separated addition of the two agents by 4 hours to preclude direct physical interaction of the antibody and drug, however, no effect of order of addition within 4 hours was observed with rituximab and gemcitabine (data not shown).

**Cell cycle alteration by gemcitabine and rituximab**
Continuous exposure to 2.5 nM gemcitabine led to accumulation of DoHH2 cells in the S phase, as has been generally reported for gemcitabine [24]. WSU-FSCCL cells, however, accumulated in the G2/M phase of the cell cycle (Figure 2). Although rituximab alone had no significant cell cycle effects on either cell line, nor on the S phase accumulation of DoHH2 cells, the combination of gemcitabine + rituximab led to S phase accumulation of WSU-FSCCL cells. Statistical analysis of S phase block in WSU-FSCCL cells comparing 2.5 nM gemcitabine alone versus gemcitabine plus rituximab revealed p < 0.001. Thus, the combination had different cell cycle effects on WSU-FSCCL than did either agent alone. The precise basis of this change is unclear, though presumably involves an alteration in the S phase DNA damage sensor, which appears to involve the ATM gene [25].

**Apoptosis induced by gemcitabine and rituximab**
Apoptosis was assayed by annexin V staining, which detects the altered location of phosphatidyl serine to the outer surface of the cell membrane. Apoptosis was induced at modest levels by gemcitabine or rituximab, but significantly more apoptosis was induced by the combination in both cell lines studied (Figure 3). When apoptosis was separated into early apoptosis, in which cells still exclude propidium iodide (PI), and late apoptosis where cells are PI permeable, early apoptosis is induced by the combination in DoHH2 cells, whereas both early and late apoptosis are demonstrated in WSU-FSCCL cells.

Apoptosis was also assessed by cleavage of PARP, which occurs when the apoptotic pathway is activated, eventually leading to cleavage of caspase 3 and of other downstream proteins including PARP. In each cell line,
rituximab and gemcitabine result in PARP cleavage, with additional cleavage using the combination (Fig 4).

**In vivo efficacy of gemcitabine ± rituximab**

We initially screen for efficacy of therapy in our model by assessing the prevention of growth of cells in ascites fluid [11,17]. The lymphomas grow as bulky mesenteric nodes with development of hepatosplenomegaly, as well as diffuse adenopathy elsewhere, but not with measurable disease. While ascites represents only a small part of the animals' disease burden, it can be repeatedly sampled as an indicator of overall tumor in a mouse. Given the differing rates of growth of the cell lines in mice, treatment was started on day 3 after DoHH2 cell injection and day 7 after WSU-FSCCL cell injection. For DoHH2 (Figure 5A), gemcitabine delayed growth, so that at day 18 there were fewer lymphoma cells in the ascites fluid, however, by day 32 there was no longer a difference. Rituximab is effective in this model, although cells do eventually reaccumulate in ascites. There is a trend to longer time to recurrence of lymphoma cells with combined therapy. In the WSU-FSCCL model (Figure 5B), while gemcitabine alone had no effect, it did enhance the rituximab-mediated delay in lymphoma cell re-growth.

The most important endpoint for treatment efficacy, since there is not an externally measurable lesion, is survival of mice bearing the human lymphoma cell lines. We have performed duplicate experiments using mice injected with DoHH2 cells (Figure 6). At the gemcitabine dose of 120
µg/gm (~ 2.4 mg/mouse), used in previous reports [26] weekly for 3 doses, there was modest prolongation of median survival, with 0/5 and 2/6 long-term survivors in the two experiments. We used sub-maximally tolerated doses of rituximab, 5 µg per mouse, which had modest therapeutic effect (1/11 long-term survivors combined). Combination therapy with these two agents at the same dose and schedule, however, markedly prolonged survival (p = 0.04, left; p = 0.01, right for rituximab + gemcitabine vs rituximab), and cured 9 of 11 mice. The surviving mice were euthanized at the end of the experiment and found to be histologically negative for lymphoma.

**Discussion**

This report demonstrates the anti-lymphoma activity of the pyrimidine analog gemcitabine *in vitro* and in a *scid* mouse human lymphoma xenograft model. Rituximab is an active therapy for CD20+ NHL as a single agent and in combination with some biologic and chemotherapeutic agents [9-12]. The generalizability and mechanism of chemosensitization by rituximab has not been fully explored. Evidence for several mechanisms of rituximab mediated lymphoma cell death has been presented including direct induction of apoptosis, complement mediated killing and antibody-dependent cell mediated cytotoxicity (ADCC). Much of the data addressing these...
processes comes from *in vitro* systems, and the relevance to activity in patients remains uncertain. Our *in vitro* data in this report rely only on direct apoptosis, as we do not add human serum as a complement source nor effector cells. Direct apoptosis can be affected by degree of crosslinking of the antibody, which in turn can be controlled by humoral or cell surface molecules. Complement activity may be altered by inhibitory factors and may differ between human serum in vitro and mouse complement in murine models. We have found that crosslinking does enhance the degree of apoptosis after rituximab treatment in our two cell lines, while addition of complement has little effect (data not shown). ADCC depends on effector cells, and even the precise effector cells remain uncertain. *Scid* mice have residual granulocytes and NK cells, and depletion of these cells can abolish rituximab efficacy [27]. To understand the mechanisms of resistance to rituximab will require more complete knowledge of which of these mechanisms of action is or are most important in patients [15]. Recent data suggests that rituximab can alter intracellular signaling, even without inducing apoptosis, in ways that can sensitize cells to chemotherapy effects [16].

Our results demonstrate that the combination of gemcitabine and rituximab inhibits NHL cell growth, induces apoptosis in these cells, and, most importantly, is effective in prolonging survival of mice bearing human t(14;18)+ lymphoma cells. Prior reports have shown additive effects of gemcitabine and rituximab in aggressive NHL cell lines *in vitro* [10]. In that report, aggressive NHL cell lines that were relatively resistant to both gemcitabine and rituximab were pre-treated with rituximab for 24 hours and then treated with gemcitabine for 18 hours and found to have modest increases in hypodiploid cells and PI positive cells after PI staining.

The cell cycle changes seen after gemcitabine treatment alone, and in combination with rituximab, are cell line dependent. WSU-FSCCL cells, in contrast to most cells, are not blocked in S phase by gemcitabine alone, but are after rituximab is added. This may reflect altered
intracellular signaling that could restore a putative S phase DNA damage sensor, such as the ATM pathway [25]. Similarly, induction of early versus late apoptosis is also cell line dependent. Further exploration of the biochemical basis of these changes is warranted to better understand which of the many potential targets of a pyrimidine nucleoside analog are the important determinants of gemcitabine activity against NHL cells, and how these targets are affected by rituximab.

Figure 5
Clearance of NHL cells from ascites by treatment with gemcitabine and rituximab. Scid mice were injected intraperitoneally (ip) with $5 \times 10^6$ DoHH2 cells (A, top) or $10 \times 10^6$ WSU-FSCCL cells (B, bottom). Mice received 20 µg rituximab (ip) on day 3 and 120 µg gemcitabine/gm body weight (ip) on day 4 after injection of DoHH2 cells. Ascites was collected on day 18, 32 and 42. Untreated scid/DoHH2 mice died prior to day 42. Because of the slower development of lymphoma with WSU-FSCCL, mice were treated with 100 µg rituximab (ip) on day 7 and 120 µg gemcitabine/gm body weight (ip) on day 8 after injection of WSU-FSCCL cells. Ascites was collected on days 22, 34 and 51. Cells from ascites were stained with PE anti-human CD45 antibody and analyzed by flow cytometry.
Concurrent treatment of B cell lymphoproliferative disorders (NHL and CLL) with rituximab and chemotherapy is becoming more common, and data suggests benefit in time to disease progression in indolent disease [14] and also in overall survival in aggressive disease [13]. Questions remain regarding the optimal way to combine rituximab and chemotherapy and whether therapeutic efficacy of specific chemotherapeutic agents is enhanced by rituximab. Pre-clinical studies of the interaction of chemotherapeutic agents and rituximab may provide insight to guide the development of appropriate clinical trials.

Competing interests
There were no competing interests at the time this work was carried out. Subsequently, Dr. Obasaju has become employed by Lilly, maker of gemcitabine, but Lilly provided no support for this work.

Authors’ contributions
MS conceived the study, provided oversight of the lab and wrote the manuscript. IJ designed and carried out the experiments and critiqued the manuscript. FJ assisted in carrying out the experiments and critiqued the manuscript. CO helped in the conception of the studies and critiqued the manuscript.

Acknowledgements
This work was supported by NIH RO1CA71552, Fox Chase Cancer Center Core Grant NIH CA06927 and grants from the Mary L. Smith Charitable Lead Trust and the Martha Rogers Charitable Trust. Additional support came from the Janice Charach Epstein Research Fund and the Lester I. Smith Research Fund. Kathy Zenszer provided excellent secretarial assistance.

References
1. Smith MR: Non-Hodgkin’s Lymphoma.  *Curr Probl Cancer* 1996, 20:6-77.
2. Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD, Norman AR, Wotherspoon AC, Koh DM, Gill K, Uzzell M, Prior Y, Catovsky D: Gemcitabine, dexamethasone, and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin’s and non-Hodgkin’s lymphoma. *British Journal of Haematology* 2003, 120:970-977.
3. Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Irrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R: Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A Phase II study by the
National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004, 101:1835-1842.

4. Guilmette C, Schorschkegger F, Solal-Cellengy P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Heguet O, Salles G, Coffier B: Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. British Journal of Haematology 2001, 113:772-778.

5. Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P: Pilot study of fixed-dose rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma 2004, 5:45-49.

6. Fossa A, Santoro A, Hiddemann W, Truempler L, Niederle N, Buksma S, Bonodonna G, Seebet S, Nowroussian MR: Gemcitabine as a Single Agent in the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 1999, 17:3786-3792.

7. Nabhan C, Kretz N, Gandhi V, Rosen S: Gemcitabine in hematolymphoid malignancies. Curr Opin Oncol 2001, 13:514-521.

8. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 1998, 16:2828-2833.

9. Alas S, Ng CP, Bonavida B: Rituximab Modifies the Cisplatin-mitochondrial Signaling Pathway, Resulting in Apoptosis in Cisplatin-resistant Non-Hodgkin's Lymphoma. Clinical Cancer Research 2002, 8:836-845.

10. Emmanouilides C, Jazirehi AR, Bonavida B: Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002, 17:621-630.

11. Smith MR, Fang J, Joshi I: Enhanced efficacy of therapy with anti-sense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. Molecular Cancer Therapeutics 2004, 3:1693-1699.

12. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177-186.

13. Esser H, LePage E, Briere J, Hebrard P, Tilly H, Bousddally R, Morel P, Van Den Nest E, Salles G, Gaulard P, Reyes F, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Eng J Med 2002, 346:239-242.

14. Box JC, Rai KR, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9172 and CALGB 9011. Blood 2005, 105:49-53.

15. Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359-7368.

16. Jazirehi AR, Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005, 24:121-2143.

17. Smith MR, Xie T, Zhao-Zong Z, Joshi I: Efficacy of treatment with antisense oligonucleotides complementary to immunoglobulin sequences of bcl-2/immunoglobulin fusion transcript in a t(14;18) human lymphoma-scid mouse model. Clinical Cancer Research 2001, 7:400-406.

18. Klun-Nellemans HC, Limens J, Mebraux J, Beverstock GC, Jansen JH, de Jong D, Klun PM: A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18) (q32;q21). Leukemia 1991, 5:221-224.

19. Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, Al-Katib A: A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet 1993, 70:62-67.

20. Freid J, Perez AG, Clarkson BD: Rapid hypotonic method for flow cytfluorometry of monolayer cell cultures. Some pitfalls in staining and data analysis. Journal of Histochemical Cytochemistry 1978, 26:921-933.

21. Brugge JS, Erikson RL: Identification of a transformation-specific antigen induced by an avian sarcoma virus. Nature 1977, 269:346-348.

22. Choi TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.

23. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipel G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E: Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 2002, 87:33-43.

24. Shi Z, Azuma A, Sampath D, Li YX, Huang P, Plunkett W: S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystauroporosine. Cancer Research 2001, 61:1065-1071.

25. Barrek J, Lukas C, Lukas J: Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 2004, 5:792-804.

26. Nowak AK, Robinson BW, Lake RA: Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Research 2002, 62:2353-2358.

27. Hernandez-liluzituri FJ, Lupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS: Neutrrophils contribute to the biologic tumor activity of rituximab in a non-Hodgkin’s lymphoma severe combined immunodeficiency mouse model. Clinical Cancer Research 2003, 9:5866-5873.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/5/103/prepub

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp